The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement
Science, Data Form Backbone
ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.
You may also be interested in...
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.